Mycophenolate mofetil

Chemical formula: C₂₃H₃₁NO₇  Molecular mass: 433.495 g/mol  PubChem compound: 5281078

Therapeutic indications

Mycophenolate mofetil is indicated for:

Prophylaxis of acute rejection of renal transplant

Population group: only adults (18 years old or older)

Mycophenolate mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of acute rejection of hepatic transplant

Population group: only adults (18 years old or older)

Mycophenolate mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic hepatic transplants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of acute rejection of renal transplant

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Mycophenolate mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of acute rejection of cardiac transplant

Population group: only adults (18 years old or older)

Mycophenolate mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic cardiac transplants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Mycophenolate mofetil is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: CELLCEPT Powder for concentrate for solution for infusion
Summary of Product Characteristics (SPC) 2019: CELLCEPT Capsules, hard
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈